Humacyte (HUMAW) Stock Price, News & Analysis

Company Overview

Humacyte, Inc. (NASDAQ:HUMAW) is a clinical-stage biotechnology company specializing in the development and manufacture of human acellular vessels (HAVs). These off-the-shelf, bioengineered vascular conduits are designed to serve as living implants for patients requiring vascular access, including those undergoing hemodialysis, as well as for peripheral artery disease and vascular trauma. Humacyte’s proprietary tissue-engineering platform leverages human vascular cells cultured on biodegradable scaffolds, which are subsequently decellularized to produce durable, non-immunogenic vessels that support natural tissue regeneration.

Founded in 2007 and headquartered in Durham, North Carolina, Humacyte has advanced its lead candidate, the HAV, through multiple clinical trials in the United States and Europe. The company’s research collaborations include partnerships with academic institutions and pharmaceutical companies to explore the broader application of its technology in cardiovascular disease. Humacyte operates a state-of-the-art manufacturing facility in North Carolina, enabling scalable production and rigorous quality control under current good manufacturing practices (cGMP).

Under the leadership of a management team with extensive experience in regenerative medicine and biomanufacturing, Humacyte is focused on obtaining regulatory approvals and expanding access to its HAV products globally. As it progresses through pivotal clinical studies, the company aims to address significant unmet needs in vascular surgery and end-stage renal disease, offering patients a novel alternative to synthetic grafts and allografts.

Key Stats

• Today's Range: $0.05 to $0.06
• 50-Day Range: $0.05 to $0.12
• 52-Week Range: $0.04 to $0.60
• Volume: 2,120 shs
• Average Volume: 14,779 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 6/08/2026
• Next Earnings (Estimated): 8/17/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HUMAW
• CIK: 1818382
• Web: www.humacyte.com
• Phone: 919-313-9633
• Fax: N/A
• Employees: 150
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $2.02 million
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A